Latest Content

While clinicians prioritize rapid regrowth, patients with alopecia areata prioritize safety and shared decision-making.

Phase 3 data show povorcitinib delivers rapid lesion clearance in HS, improves quality of life outcomes, and offers favorable safety through 24 weeks.

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor.

The Conference on Retroviruses and Opportunistic Infections 2026 included breakthrough research and looked toward the future of HIV.

The data in these posters address a central clinical question: can a topical JAK1/JAK2 inhibitor deliver robust efficacy while maintaining a reassuring safety profile?

Jody L. Green, PhD, explains how regulatory decisions shape medication safety amid uptake of OTC drugs.

National data reveal increasing rates of type 1 and type 2 diabetes among children insured through Medicaid and CHIP.

Patients with myasthenia gravis had a more consistent clinical response and fewer deteriorations when using add-on therapy early.

AI-enabled coronary CT angiography reveals total plaque burden beyond calcium scores, improving risk prediction and personalizing cardiovascular prevention.